This paper provides an overview of Crohn's disease (CD) and ulcerative colitis (UC), the two primary forms of chronic inflammatory bowel disease (IBD). It examines shared and distinct symptoms, diagnostic approaches, and the genetic factors that may predispose individuals to each condition. The paper also reviews current treatment options, including medications and surgical interventions, and discusses research into disease-specific genetic loci. A patient-care scenario involving a newly diagnosed UC patient is used to illustrate the clinical implications of both conditions, highlighting the importance of honest, informed communication and cautious optimism in patient management.
Crohn's disease (CD) and ulcerative colitis (UC) are the major forms of chronic inflammatory bowel disease (IBD) in the western world, occurring in young adults with an estimated prevalence of more than one per thousand inhabitants (Hugot et al., 1996). These diseases can affect any portion of the gastrointestinal system, from the mouth to the anus, and are associated with many other medical problems such as arthritis, skin conditions, cancer, and kidney stones. Ulcerative colitis is most likely to be diagnosed in early adolescence, while Crohn's disease is more commonly diagnosed between the ages of fifteen and thirty, though it can more rarely be diagnosed later in life. Both diseases are still being researched thoroughly, and many questions remain.
The most common symptoms of IBD include abdominal pain, cramping, and diarrhea. In more severe cases, symptoms may also include rectal bleeding, urgent bowel movements, constipation, and recurring fever. Most physicians diagnose IBD through a series of blood tests to determine whether certain antibodies are present and to identify which type of inflammatory bowel disease the patient has. Blood tests reveal particular signs of an immune response associated with inflammation and intestinal disease. In some cases, stool samples are collected to examine stool content, and a colonoscopy may be performed to examine the intestines directly. The presence of white blood cells in a patient's stool indicates some type of inflammatory disease, which can then be further investigated to determine whether it has arisen from an IBD.
One study examined whether the use of antibiotics two to five years before diagnosis was associated with the development of IBD, and found that subjects diagnosed with IBD were more likely to have been prescribed antibiotics during that window (Shaw, Blanchard, & Bernstein, 2011). This finding possibly implicates antibiotic use as a predisposing factor in IBD etiology. However, many other potential contributing factors are also under investigation. There is also evidence suggesting a greater risk of IBD if a close relative has the disease, indicating a strong genetic component.
Research is also being conducted to identify disease-specific loci for Crohn's disease and UC. Identifying shared and disease-specific susceptibility loci would help define the biological relationship between these two inflammatory bowel diseases. More than 30 CD susceptibility loci have been identified, representing important candidate loci for UC as well. Loci discovered by index genome scans in CD have previously been tested for association with UC, but those identified in recent meta-analyses have yet to be fully investigated in that context. One study analyzed 45 single nucleotide polymorphisms, tagging 29 of the loci recently associated with CD in 2,527 UC cases and 4,070 population controls. Collectively, such data help clarify the genetic relationship between CD and UC and characterize both common and disease-specific mechanisms of pathogenesis (Anderson & al., 2009).
"Key anatomical and inflammatory distinctions"
"Medications and surgical interventions for IBD"
"Applying IBD knowledge in patient care scenarios"
Always verify citation format against your institution’s current style guide requirements.